David Jensen reports on the future of CIRM as a “beautiful machine”.
CIRM funds brain cancer research in a big way: Funding a clinical trial for deadly cancer is a no brainer. Glioblastoma is a fatal tumor that needs new clinical approaches so this is exciting. One of the goals of my lab is to find new pathways to treat glioblastoma in children.
Jacob Corn of IGI has a Wish List for Science on CRISPR science, but also science more generally.
The case for possibly retracting a retraction over at RetractionWatch.
Take another look at last year’s Takaho Endo paper, which was a major step toward debunking STAP so why did the new paper in Nature debunking STAP using similar approach not cite Dr. Endo’s 2014 paper? I’m glad to see that the other new Nature paper did cite Dr. Endo’s paper.
Pete Shanks over at BioPolitical Times from CGI has concerns about balance at upcoming NAS meeting on human gene editing.
Zhang’s lab reports on Cpf1, a useable new CRISPR partner protein in place of Cas9 and Antonio Regalado has the backstory: New CRISPR Protein Slices through Patent Problems
The Node on Enabling research with human embryonic and fetal tissue resources
MIT Technology Review article – WOW! Feng Zhang and one of his colleagues have awesome black lab coats! The plaid lab coat in the background doesn’t match my eyes, but might work for Paul.
Hi Paul,
the link in your sentence “The case for possibly retracting a retraction over at RetractionWatch.” does not work.
Thanks, George. Fixed!
Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax®-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol. Sounds very similar but further along. Yes?